Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease

Journal of Immunology

Volumn 188, Issue 10, 2012, Pages 5142-5149

  Kavian, Niloufar ^a,b   Marut, Wioleta ^a   Servettaz, Amélie ^a,c   Laude, Hélène ^a,b   Nicco, Carole ^a   Chéreau, Christiane ^a   Weill, Bernard ^a,b   Batteux, Frédéric ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Assistance Publique Hôpitaux de Paris ^*  (France)

^c SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; REACTIVE OXYGEN METABOLITE;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; IRRADIATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SCLERODERMA; SCLERODERMATOUS GRAFT VERSUS HOST REACTION; SKIN FIBROSIS; SPLEEN CELL; TREATMENT RESPONSE; VASCULITIS;

ANIMALS; ARSENICALS; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GRAFT VS HOST DISEASE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OXIDES; RANDOM ALLOCATION; SCLERODERMA, SYSTEMIC; SPLEEN;

EID: 84861181733     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103538     Document Type: Article

References (34)

1. Lee, S. J., J. P. Klein, A. J. Barrett, O. Ringden, J. H. Antin, J. Y. Cahn, M. H. Carabasi, R. P. Gale, S. Giralt, G. A. Hale, et al. 2002. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100: 406-414. (Pubitemid 34761100)
2. Baird, K., and S. Z. Pavletic. 2006. Chronic graft versus host disease. Curr. Opin. Hematol. 13: 426-435. (Pubitemid 44607443)
3. Coghill, J. M., S. Sarantopoulos, T. P. Moran, W. J. Murphy, B. R. Blazar, and J. S. Serody. 2011. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 117: 3268-3276.
4. Korngold, R., and J. Sprent. 1978. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 148: 1687-1698. (Pubitemid 9084041)
5. Duffner, U. A., Y. Maeda, K. R. Cooke, P. Reddy, R. Ordemann, C. Liu, J. L. Ferrara, and T. Teshima. 2004. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J. Immunol. 172: 7393-7398. (Pubitemid 38747600)
6. Koyama, M., D. Hashimoto, K. Aoyama, K. Matsuoka, K. Karube, H. Niiro, M. Harada, M. Tanimoto, K. Akashi, and T. Teshima. 2009. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood 113: 2088-2095.
7. Filipovich, A. H., D. Weisdorf, S. Pavletic, G. Socie, J. R. Wingard, S. J. Lee, P. Martin, J. Chien, D. Przepiorka, D. Couriel, et al. 2005. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11: 945-956. (Pubitemid 41754712)
8. Vogelsang, G. B., L. Lee, and D. M. Bensen-Kennedy. 2003. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu. Rev. Med. 54: 29-52. (Pubitemid 37386384)
9. Ruzek, M. C., S. Jha, S. Ledbetter, S. M. Richards, and R. D. Garman. 2004. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum. 50: 1319-1331. (Pubitemid 38480843)
10. Sanz, M. A., D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Büchner, H. Döhner, et al. 2009. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113: 1875-1891.
11. Miller, W. H., Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman. 2002. Mechanisms of action of arsenic trioxide. Cancer Res. 62: 3893-3903. (Pubitemid 34792653)
12. Lynn, S., J. R. Gurr, H. T. Lai, and K. Y. Jan. 2000. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ. Res. 86: 514-519. (Pubitemid 30165042)
13. Smith, K. R., L. R. Klei, and A. Barchowsky. 2001. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 280: L442-L449.
14. Pelicano, H., L. Feng, Y. Zhou, J. S. Carew, E. O. Hileman, W. Plunkett, M. J. Keating, and P. Huang. 2003. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278: 37832-37839. (Pubitemid 37175311)
15. Tse, W. P., C. H. Cheng, C. T. Che, and Z. X. Lin. 2008. Arsenic trioxide, arsenic pentoxide, and arsenic iodide inhibit human keratinocyte proliferation through the induction of apoptosis. J. Pharmacol. Exp. Ther. 326: 388-394.
16. Chen, Y. C., S. Y. Lin-Shiau, and J. K. Lin. 1998. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell. Physiol. 177: 324-333.
17. Bobé, P., D. Bonardelle, K. Benihoud, P. Opolon, and M. K. Chelbi-Alix. 2006. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 108: 3967-3975. (Pubitemid 44913262)
18. Kavian, N., A. Servettaz, C. Mongaret, A. Wang, C. Nicco, C. Che'reau, P. Grange, V. Vuiblet, P. Birembaut, M. D. Diebold, et al. 2010. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 62: 3477-3487.
19. Jaffee, B. D., and H. N. Claman. 1983. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell. Immunol. 77: 1-12. (Pubitemid 13135593)
20. Dubois, M. F., V. Mezger, M. Morange, C. Ferrieux, P. Lebon, and O. Bensaude. 1988. Regulation of the heat-shock response by interferon in mouse L cells. J. Cell. Physiol. 137: 102-109.
21. Hill, G. R., S. D. Olver, R. D. Kuns, A. Varelias, N. C. Raffelt, A. L. Don, K. A. Markey, Y. A. Wilson, M. J. Smyth, Y. Iwakura, et al. 2010. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 116: 819-828.
22. McCormick, L. L., Y. Zhang, E. Tootell, and A. C. Gilliam. 1999. Anti-TGFbeta treatment prevents skin and lung fibrosis in murine sclerodermatous graftversus- host disease: a model for human scleroderma. J. Immunol. 163: 5693-5699.
23. Chu, Y. W., and R. E. Gress. 2008. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol. Blood Marrow Transplant. 14: 365-378.
24. Shlomchik, W. D. 2007. Graft-versus-host disease. Nat. Rev. Immunol. 7: 340-352. (Pubitemid 46674485)
25. Kappel, L. W., G. L. Goldberg, C. G. King, D. Y. Suh, O. M. Smith, C. Ligh, A. M. Holland, J. Grubin, N. M. Mark, C. Liu, et al. 2009. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 113: 945-952.
26. Kansu, E. 2004. The pathophysiology of chronic graft-versus-host disease. Int. J. Hematol. 79: 209-215. (Pubitemid 38620767)
27. Davison, K., S. Côté, S. Mader, and W. H. Miller. 2003. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17: 931-940. (Pubitemid 36626322)
28. Nishimori, H., Y. Maeda, T. Teshima, H. Sugiyama, K. Kobayashi, Y. Yamasuji, S. Kadohisa, H. Uryu, K. Takeuchi, T. Tanaka, et al. 2012. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood 119: 285-295.
29. Asumendi, A., M. C. Morales, A. Alvarez, J. Aréchaga, and G. Pérez-Yarza. 2002. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Br. J. Cancer 86: 1951-1956.
30. Zhou, L., D. Askew, C. Wu, and A. C. Gilliam. 2007. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J. Invest. Dermatol. 127: 281-292. (Pubitemid 46106903)
31. Wynn, T. A. 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4: 583-594.
32. Anderson, B. E., J. M. McNiff, D. Jain, B. R. Blazar, W. D. Shlomchik, and M. J. Shlomchik. 2005. Distinct roles for donor- and host-derived antigenpresenting cells and costimulatory molecules in murine chronic graft-versushost disease: requirements depend on target organ. Blood 105: 2227-2234. (Pubitemid 40731817)
33. MacDonald, K. P., V. Rowe, C. Filippich, R. Thomas, A. D. Clouston, J. K. Welply, D. N. Hart, J. L. Ferrara, and G. R. Hill. 2003. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood 101: 2033-2042. (Pubitemid 36237611)
34. Banovic, T., K. A. Markey, R. D. Kuns, S. D. Olver, N. C. Raffelt, A. L. Don, M. A. Degli-Esposti, C. R. Engwerda, K. P. MacDonald, and G. R. Hill. 2009. Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells. J. Immunol. 182: 912-920.